[1] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2024; 74, 229−63. doi:  10.3410/f.739487650.793592245
[2] O'Keeffe LM, Taylor G, Huxley RR, et al. Smoking as a risk factor for lung cancer in women and men: a systematic review and meta-analysis. BMJ Open, 2018; 8, e021611. doi:  10.1136/bmjopen-2018-021611
[3] Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet, 2005; 365, 1415−28. doi:  10.1016/S0140-6736(05)66378-7
[4] Saklayen MG. The global epidemic of the metabolic syndrome. Curr Hypertens Rep, 2018; 20, 12. doi:  10.1007/s11906-018-0812-z
[5] van Kruijsdijk RC, van der Graaf Y, Peeters PH, et al. Cancer risk in patients with manifest vascular disease: effects of smoking, obesity, and metabolic syndrome. Cancer Epidemiol Biomarkers Prev, 2013; 22, 1267−77. doi:  10.1158/1055-9965.EPI-13-0090
[6] Gathirua-Mwangi WG, Monahan PO, Murage MJ, et al. Metabolic syndrome and total cancer mortality in the Third National Health and Nutrition Examination Survey. Cancer Causes Control, 2017; 28, 127−36. doi:  10.1007/s10552-016-0843-1
[7] Li L, Meng F, Xu D, et al. Synergism between the metabolic syndrome components and cancer incidence: results from a prospective nested case-control study based on the China Health and Retirement Longitudinal Study (CHARLS). BMJ Open, 2022; 12, e061362. doi:  10.1136/bmjopen-2022-061362
[8] Van Hoang D, Inoue Y, Fukunaga A, et al. Metabolic syndrome and the risk of severe cancer events: a longitudinal study in Japanese workers. BMC Cancer, 2023; 23, 555. doi:  10.1186/s12885-023-11026-7
[9] Hursting SD, Hursting MJ. Growth signals, inflammation, and vascular perturbations: mechanistic links between obesity, metabolic syndrome, and cancer. Arterioscler Thromb Vasc Biol, 2012; 32, 1766−70. doi:  10.1161/ATVBAHA.111.241927
[10] Mendonça FM, de Sousa FR, Barbosa AL, et al. Metabolic syndrome and risk of cancer: which link? Metabolism, 2015; 64, 182-9.
[11] Maury E, Brichard SM. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol, 2010; 314, 1−16. doi:  10.1016/j.mce.2009.07.031
[12] Sin S, Lee CH, Choi SM, et al. Metabolic syndrome and risk of lung cancer: an analysis of Korean National Health Insurance Corporation database. J Clin Endocrinol Metab, 2020; 105, dgaa596. doi:  10.2139/ssrn.3448032
[13] Li M, Cao SM, Dimou N, et al. Association of metabolic syndrome with risk of lung cancer: a population-based prospective cohort study. Chest, 2024; 165, 213−23. doi:  10.1016/j.chest.2023.08.003
[14] Esposito K, Chiodini P, Colao A, et al. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care, 2012; 35, 2402−11.
[15] Qiao L, Ma D, Lv H, et al. Metabolic syndrome and the incidence of lung cancer: a meta-analysis of cohort studies. Diabetol Metab Syndr, 2020; 12, 95. doi:  10.1186/s13098-020-00598-0
[16] Watanabe J, Kakehi E, Kotani K, et al. Metabolic syndrome is a risk factor for cancer mortality in the general Japanese population: the Jichi Medical School Cohort Study. Diabetol Metab Syndr, 2019; 11, 3. doi:  10.1186/s13098-018-0398-2
[17] Pallis AG, Syrigos KN. Lung cancer in never smokers: disease characteristics and risk factors. Crit Rev Oncol Hematol, 2013; 88, 494−503. doi:  10.1016/j.critrevonc.2013.06.011
[18] Carr SR, Akerley W, Cannon-Albright LA. Genetic contribution to nonsquamous, non-small cell lung cancer in nonsmokers. J Thorac Oncol, 2018; 13, 938−45. doi:  10.1016/j.jtho.2018.03.024
[19] Bossé Y, Amos CI. A decade of GWAS results in lung cancer. Cancer Epidemiol Biomarkers Prev, 2018; 27, 363−79. doi:  10.1158/1055-9965.EPI-16-0794
[20] McKay JD, Hung RJ, Han Y, et al. Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. Nat Genet, 2017; 49, 1126−32. doi:  10.1038/ng.3892
[21] Dai J, Lv J, Zhu M, et al. Identification of risk loci and a polygenic risk score for lung cancer: a large-scale prospective cohort study in Chinese populations. Lancet Respir Med, 2019; 7, 881−91. doi:  10.1016/S2213-2600(19)30144-4
[22] Sugrue LP, Desikan RS. What are polygenic scores and why are they important? JAMA, 2019; 321, 1820-1.
[23] Wu C, Kraft P, Zhai K, et al. Genome-wide association analyses of esophageal squamous cell carcinoma in Chinese identify multiple susceptibility loci and gene-environment interactions. Nat Genet, 2012; 44, 1090−7. doi:  10.1038/ng.2411
[24] Huang Y, Zhu M, Ji M, et al. Air pollution, genetic factors, and the risk of lung cancer: a prospective study in the UK Biobank. Am J Respir Crit Care Med, 2021; 204, 817−25. doi:  10.1164/rccm.202011-4063OC
[25] Collins R. What makes UK Biobank special? Lancet, 2012; 379, 1173-4.
[26] Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement: Executive Summary. Crit Pathw Cardiol, 2005; 4, 198−203.
[27] John WG. Use of HbA1c in the diagnosis of diabetes mellitus in the UK. The implementation of World Health Organization guidance 2011. Diabet Med, 2012; 29, 1350−7. doi:  10.1111/j.1464-5491.2012.03762.x
[28] Morris DH, Khunti K, Achana F, et al. Progression rates from HbA1c 6.0-6.4% and other prediabetes definitions to type 2 diabetes: a meta-analysis. Diabetologia, 2013; 56, 1489−93. doi:  10.1007/s00125-013-2902-4
[29] Bycroft C, Freeman C, Petkova D, et al. The UK Biobank resource with deep phenotyping and genomic data. Nature, 2018; 562, 203−9. doi:  10.1038/s41586-018-0579-z
[30] Xu B, Chen L, Radojčić MR, et al. Current smoking and secondhand smoke exposure in relation to chronic post-surgical pain among UK adults: a cohort study. Int J Surg, 2025; 111, 9308−20. doi:  10.1097/JS9.0000000000003136
[31] Craig CL, Marshall AL, Sjöström M, et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc, 2003; 35, 1381−95. doi:  10.1249/01.MSS.0000078924.61453.FB
[32] WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet, 2004; 363, 157−63. doi:  10.1016/S0140-6736(03)15268-3
[33] Li R, Chambless L. Test for additive interaction in proportional hazards models. Ann Epidemiol, 2007; 17, 227−36. doi:  10.1016/j.annepidem.2006.10.009
[34] Braun S, Bitton-Worms K, LeRoith D. The link between the metabolic syndrome and cancer. Int J Biol Sci, 2011; 7, 1003−15.
[35] Inoue M, Noda M, Kurahashi N, et al. Impact of metabolic factors on subsequent cancer risk: results from a large-scale population-based cohort study in Japan. Eur J Cancer Prev, 2009; 18, 240−7. doi:  10.1097/CEJ.0b013e3283240460
[36] Russo A, Autelitano M, Bisanti L. Metabolic syndrome and cancer risk. Eur J Cancer, 2008; 44, 293−7. doi:  10.1016/j.ejca.2007.11.005
[37] Hidayat K, Du X, Chen G, et al. Abdominal obesity and lung cancer risk: systematic review and meta-analysis of prospective studies. Nutrients, 2016; 8, 810. doi:  10.3390/nu8120810
[38] Lee KR, Seo MH, Do Han K, et al. Waist circumference and risk of 23 site-specific cancers: a population-based cohort study of Korean adults. Br J Cancer, 2018; 119, 1018−27. doi:  10.1038/s41416-018-0214-7
[39] Leitzmann MF, Moore SC, Koster A, et al. Waist circumference as compared with body-mass index in predicting mortality from specific causes. PLoS One, 2011; 6, e18582. doi:  10.1371/journal.pone.0018582
[40] Pedersen KM, Çolak Y, Bojesen SE, et al. Low high-density lipoprotein and increased risk of several cancers: 2 population-based cohort studies including 116, 728 individuals. J Hematol Oncol, 2020; 13, 129. doi:  10.1186/s13045-020-00963-6
[41] Loosen SH, Kostev K, Luedde M, et al. Low blood levels of high-density lipoprotein (HDL) cholesterol are positively associated with cancer. J Cancer Res Clin Oncol, 2022; 148, 3039−46. doi:  10.1007/s00432-021-03867-1
[42] Zhang Y, Xu J, Lou Y, et al. Pretreatment direct bilirubin and total cholesterol are significant predictors of overall survival in advanced non-small-cell lung cancer patients with EGFR mutations. Int J Cancer, 2017; 140, 1645−52. doi:  10.1002/ijc.30581
[43] Srour B, Kaaks R, Johnson T, et al. Ageing-related markers and risks of cancer and cardiovascular disease: a prospective study in the EPIC-Heidelberg cohort. Eur J Epidemiol, 2022; 37, 49−65. doi:  10.1007/s10654-021-00828-3
[44] Cho IY, Chang Y, Sung E, et al. Glycemic status, insulin resistance, and mortality from lung cancer among individuals with and without diabetes. Cancer Metab, 2024; 12, 17. doi:  10.1186/s40170-024-00344-4
[45] Ulmer H, Borena W, Rapp K, et al. Serum triglyceride concentrations and cancer risk in a large cohort study in Austria. Br J Cancer, 2009; 101, 1202−6. doi:  10.1038/sj.bjc.6605264
[46] Ma C, Wang X, Guo J, et al. Prognostic significance of preoperative serum triglycerides and high-density lipoproteins cholesterol in patients with non-small cell lung cancer: a retrospective study. Lipids Health Dis, 2021; 20, 69. doi:  10.1186/s12944-021-01492-y
[47] Chandler PD, Song Y, Lin J, et al. Lipid biomarkers and long-term risk of cancer in the Women's Health Study. Am J Clin Nutr, 2016; 103, 1397−407. doi:  10.3945/ajcn.115.124321
[48] Peeters PH, van Noord PA, Hoes AW, et al. Hypertension, antihypertensive drugs, and mortality from cancer among women. J Hypertens, 1998; 16, 941−7. doi:  10.1097/00004872-199816070-00007
[49] Christakoudi S, Kakourou A, Markozannes G, et al. Blood pressure and risk of cancer in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer, 2020; 146, 2680−93. doi:  10.1002/ijc.32576
[50] Gallo G, Volpe M, Savoia C. Endothelial dysfunction in hypertension: current concepts and clinical implications. Front Med (Lausanne), 2021; 8, 798958. doi:  10.3389/fmed.2021.798958
[51] Zhang Z, Zhao L, Zhou X, et al. Role of inflammation, immunity, and oxidative stress in hypertension: new insights and potential therapeutic targets. Front Immunol, 2022; 13, 1098725. doi:  10.3389/fimmu.2022.1098725
[52] Yoshida Y, Chen Z, Baudier RL, et al. Sex differences in the progression of metabolic risk factors in diabetes development. JAMA Netw Open, 2022; 5, e2222070. doi:  10.1001/jamanetworkopen.2022.22070
[53] Rodriguez-Lara V, Avila-Costa MR. An overview of lung cancer in women and the impact of estrogen in lung carcinogenesis and lung cancer treatment. Front Med (Lausanne), 2021; 8, 600121. doi:  10.3389/fmed.2021.600121
[54] Smith R Jr, Gee KN, Kalvapudi S, et al. Sex-based differences in the lung immune microenvironment are associated with an increased risk of lung cancer in women. J Thorac Cardiovasc Surg, 2025; 169, 764-76. e9.
[55] Polański J, Chabowski M, Świątoniowska-Lonc N, et al. Relationship between nutritional status and clinical outcome in patients treated for lung cancer. Nutrients, 2021; 13, 3332. doi:  10.3390/nu13103332
[56] Hunter DJ. Gene-environment interactions in human diseases. Nat Rev Genet, 2005; 6, 287−98. doi:  10.21775/cimb.010.025
[57] He H, He MM, Wang H, et al. In utero and childhood/adolescence exposure to tobacco smoke, genetic risk, and lung cancer incidence and mortality in adulthood. Am J Respir Crit Care Med, 2023; 207, 173−82. doi:  10.1164/rccm.202112-2758OC
[58] Crudele L, Piccinin E, Moschetta A. Visceral adiposity and cancer: role in pathogenesis and prognosis. Nutrients, 2021; 13, 2101. doi:  10.3390/nu13062101
[59] Donohoe CL, Doyle SL, Reynolds JV. Visceral adiposity, insulin resistance and cancer risk. Diabetol Metab Syndr, 2011; 3, 12. doi:  10.1186/1758-5996-3-12
[60] Rudd MF, Webb EL, Matakidou A, et al. Variants in the GH-IGF axis confer susceptibility to lung cancer. Genome Res, 2006; 16, 693−701. doi:  10.1101/gr.5120106
[61] Tang W, Wang J, Dai T, et al. Association of leptin receptor polymorphisms with susceptibility of non-small cell lung cancer: evidence from 2249 subjects. Cancer Med, 2024; 13, e7178. doi:  10.1002/cam4.7178
[62] Cui E, Deng A, Wang X, et al. The role of adiponectin (ADIPOQ) gene polymorphisms in the susceptibility and prognosis of non-small cell lung cancer. Biochem Cell Biol, 2011; 89, 308−13. doi:  10.1139/o11-005
[63] Engels EA. Inflammation in the development of lung cancer: epidemiological evidence. Expert Rev Anticancer Ther, 2008; 8, 605−15. doi:  10.1586/14737140.8.4.605